Navigation Links
HSCI researchers identify another potential ALS treatment avenue
Date:8/6/2014

Cambridge, MA, Aug 6 - A series of studies begun by Harvard Stem Cell Institute (HSCI) scientists eight years ago has lead to a report published today that may be a major step forward in the quest to develop real treatments for amyotrophic lateral sclerosis, ALS, or Lou Gehrig's disease.

The findings by Harvard professor of Stem Cell and Regenerative Biology (HSCRB) Kevin Eggan and colleagues also has produced functionally identical results in human motor neurons in a laboratory dish and in a mouse model of the disease, demonstrating that the modeling of human disease with customized stem cells in the laboratory could someday relatively soon eliminate some of the need for animal testing.

The new study, published today in Science Translational Medicine, suggest that compounds already in clinical trials for other purposes may be promising candidate therapeutics for ALS. The Harvard authors found that genetically intervening in the pathway these drugs act on increased survival time of an ALS animal model 5-10 percent, and while that is a long way from curing the universally fatal neurodegenerative disease, "any ALS patient would be excited about this extended life span," said Eggan, who pioneered the disease in a dish concept.

Sophie De Boer, a graduate student in Eggan's lab, is the first author on the Science Translational Medicine paper.

This latest finding is expected to push towards clinical studies the second major ALS discovery from Eggan's lab in less than a year. The HSCI stem cell biologist, and his neuroscience and neurology collaborators at Massachusetts General Hospital and Boston Children's Hospital, are preparing for a phase I clinical trial of a medication already approved for epilepsy which Eggan and colleagues discovered quiets disease related electrical excitability in the motor neurons effected in ALS.

In a paper in 2007, Eggan and colleagues demonstrated that glial cells, background cells in the nervous system, were involved in motor neuron degeneration in a mouse model of ALS. And the following year the researchers reported that the same thing was happening in human motor neurons made from patient stem cells, and proposed that prostanoid molecules, a group of substances involved in inflammation in everything from pain to pregnancy, might be playing a role in the glial cells.

Today the researchers reported they have confirmed there is a change in prostanoid receptors in the gial cells playing a role in ALS, and with genetic and chemical experiments they showed that this is playing a role in ALS. They further report that when the effected receptor is blocked, the ALS damage done by the glial cells is reduced.

This latest work, says Eggan, first done in human motor neurons in a dish, and then in a mouse model of ALS, "says that indeed this stem cell model was predictive of something that can happen inside a whole animal, and its important because it demonstrates that this is really an important target for an ALS therapeutic. If we can inhibit this receptor in an ALS patient, we might slow down the progression of the disease, and that would be a huge step."

Eggan said "one feature of the glial cells in ALS that attack motor neurons is that they have higher expression of this prostanoid receptor. Removing just one of the two copies of the receptor in the glial cells had an effect on extending the life span" of the ALS mice," Eggan said, and "inhibition by a drug is unlikely to have an effect as complete as a knockout in the mice."

Eggan said that experiments on human stem cell-generated ALS motor neurons also show that "if we inhibit that receptor in the ALS cells with a chemical, those cells lose their toxicity to motor neurons

"This is a very exciting period for those whose lives are threatened by ALS, and it is exciting for my lab," Eggan said. "First we recently identified a pathway that we think is important for degeneration inside the motor neuron, and now we've found this pathway in cells outside the motor neuron. This has potential to have a very substantial effect on what's happening in ALS."

The research was funded by Project ALS, the New York Stem Cell Foundation, P2ALS, and the Howard Hughes Medical Institute.


'/>"/>

Contact: B. D. Colen
617-495-7821
Harvard University
Source:Eurekalert  

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
3. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
4. UNH researchers find African farmers need better climate change data to improve farming practices
5. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
6. Researchers uncover molecular pathway through which common yeast becomes fungal pathogen
7. Researchers print live cells with a standard inkjet printer
8. Columbia Engineering and Penn researchers increase speed of single-molecule measurements
9. Researchers reveal how a single gene mutation leads to uncontrolled obesity
10. Researchers discover novel therapy for Crohns disease
11. New paper by Notre Dame researchers describes method for cleaning up nuclear waste
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
HSCI researchers identify another potential ALS treatment avenue
(Date:1/26/2017)... , Jan. 26, 2017  Crossmatch, a leading provider ... new solution aimed at combatting fraud, waste and abuse ... introduced at the Action on Disaster Relief conference in ... point for UN agencies and foreign assistance organizations throughout ... waste and abuse are a largely unacknowledged problem in ...
(Date:1/25/2017)... The Elements of Enterprise Information Security ... of a comprehensive set of business processes and ... identities and providing a secured and documented access ... number of programs opted by enterprises to maintain ... processes and changing policies. However, there are some ...
(Date:1/24/2017)... Jan. 24, 2017  It sounds simple and ... that monitors vital signs and alerts parents on ... oxygen saturation level drops. But pediatric experts argue ... parents, with no evidence of medical benefits, especially ... marketed aggressively to parents of healthy babies, promising ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... 2017 Aethlon Medical, Inc. (Nasdaq: ... that validated the ability of the Aethlon Hemopurifier® to ... mortality in immune-suppressed sepsis patients and also contribute to ... objective of the study was to validate the ... (EBV) and Herpes Simplex virus 1 (HSV1) by the ...
(Date:2/21/2017)... Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company ... the health of patients, intends to report operational highlights and financial ... 2, 2017, and to host a conference call the same day ... as follows: U.S. (toll free): 1-888-347-5280 International: +1 ... Participants ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... Trevor Heritage has joined its executive team to lead the development and commercialization ... insights to help improve the diagnosis and treatment of cancer. The CIDT addresses ...
(Date:2/21/2017)... and VANCOUVER, British Columbia , ... OGXI ) today announced that apatorsen results from two randomized ... of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium, held February ... . Clinical data from trials in bladder and prostate ... administered in combination with standard-of-care treatments. ...
Breaking Biology Technology: